Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing Regimen.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 16 Sept 2025

Montrouge Thomas, Bertine Mélanie, Peytavin Gilles, Saint-Joannis Thibault, Bachelard Antoine, De Truchis Pierre, Lariven Sylvie, Morlat Philippe, Pouderoux Cécile, Damond Florence, Sayre Naomi, Tubiana Roland, Valin Nadia, Charpentier Charlotte, Descamps Diane, Ghosn Jade, Le Hingrat Quentin

Abstract excerpt

Lenacapavir is the first capsid inhibitor and its use is currently approved for multidrug-resistant human immunodeficiency virus-1 infection. We report that, despite the initial efficacy of a lenacapavir-containing regimen in patients with multidrug-resistant human immunodeficiency virus-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug resistance-associated...

Topics

Join the communities discussing this publication.

HIV/AIDS drug development and treatment
HIV/AIDS Research and Interventions
HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39737782
DOI: 10.1093/cid/ciae650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing RegimenPMID 39737782Read ↗

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

Rapid HIV-1 genotyping assay for the detection of capsid mutations.Semantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity Read ↗

Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir.Semantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity Read ↗

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisSemantic proximity Read ↗

Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.Semantic proximity Read ↗

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity Read ↗

Lenacapavir binding to immature Gag triggers the emergence of giant HIV-1 virionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.